Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Blueprint Medicines
Deal Size : $1,670.0 million
Deal Type : Expanded Collaboration
VantAI Expands Drug Discovery Deal with Blueprint Medicines in Induced Proximity
Details : The collaboration aims to pursue targets and mechanisms that have historically been considered undruggable or out of reach for traditional small-molecule or biologic therapeutics.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 20, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Blueprint Medicines
Deal Size : $1,670.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $674.0 million
Deal Type : Collaboration
VantAI and Bristol Myers Squibb Collaborate on AI-Driven Molecular Glue Drug Discovery
Details : The collaboration will focus on leveraging VantAI’s generative AI platform with BMS’s expertise in targeted protein degradation to discover and design molecular glues as small molecule therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 13, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $674.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders
Details : The organizations will leverage VantAI's geometric deep learning platform to computationally streamline the design of new molecules optimized for each E3 platform, leveraging unique target-E3 interface contacts to create innovative routes for important d...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration